As of August 31, 2011, pharmaceutical companies publish semi-annual report completed in 2011, we counted the medical section of 162 companies that have comparable data and the sub-section of key financial indicators.
PharmaceuticalChina medical thermometer manufacturer sector in the first half operating income increased by 23.91%, compared with 1 to 6 months 30.03% of the pharmaceutical manufacturing sector growth rate slow. Total profits of listed companies increased by 23.14%, slightly faster than the pharmaceutical industry growth. The entire pharmaceutical sector gross margin decreased 2.53%, but operating margin fell by only 0.15%. If we exclude the bulk drug sector data, the pharmaceutical sector's total profit growth rate reached 34.13%, attributable to the parent company's net profit rose 33.20%, excluding non-recurring gains and losses attributable to the parent company's net profit rose 23.06%.
Medical condition of the growth of different sub-sectors, including health care sector performance is outstanding.
Chemical China rapid thermometer raw materials: raw materials by the same period in 2010 most of the impact of drug prices are high, especially heparin, vitamin C, a relatively large price decline year on year, Hai Purui, North China Pharmaceutical, Northeast Pharmaceutical, year profits have dropped significantly, lead to revenueChina ear thermometer manufacturer growth 19% of chemical raw materials in the case, the net profit attributable to parent company declined 15.78%.
Chemical medicine preparation: the first six months of income growth rate of 19.39%, slightly slower than a quarter, gross margins declined slightly, but the net profit attributable to parent company is still up 26.18% year on year growth, after deducting non-recurring gains and losses China digital blood pressure monitor manufacturer The net profit rose 19.79%.
Chinese medicine: the first half segment revenue grew 22.72%, relatively slow. Net profit attributable to parent company growth rate reached 31.39%,China digital sphygmomanometer manufacturer profit after deducting China digital sphygmomanometer non-recurring net profit rose 27.01%, of which, Health America Pharmaceutical, donkey-hide gelatin, such as constant group net profit increased considerably.
Biopharmaceuticals: the first half of biopharmaceutical revenues increased by only 8.74%, growth is slowing down, growth in net profit attributable to parent company 22.87%, also has slowed, net profit after non-recurring net profit increased by only 2.89% mainly affected by Hualan performance decline.
Medical equipment: plate revenue growth 32.62%, outstanding, net profit attributable to parent up 22.87%, excluding non-recurring net profit increased 21.73% after the relatively stable.
Medical services: plate revenue outstanding profit growth, revenue growth 61.58%, net profit attributable to parent company increased 58.77%, after deducting non-recurring gains and losses increased 68.48%. Ireland Eye, profit growth through health policy in more than 50%.
Pharmaceutical business: 22.75% revenue growth plate, growth in net profit attributable to parent company, 56.94%, mainly in Shanghai Fosun contribution to medicine and, after deducting non-recurring gains and losses, compared with only 21.83% net profit growth.
From the company perspective, the mid-2011, attributable to the parent company's net profit rose more than 30% of the 64 companies, mainly in the following categories: 1. Main income growth: two-Heron Pharmaceutical, the constant group, Huahai medicine, Xinhua medical, Kunming Pharmaceutical, HEALTH, Hai Kai Bao, Han-medicine, medicine Cologne, Ireland Eye, the sea is medicine, health policy through, diving medical; 2 Investment revenue contribution to profits: Qinghai Gelation, Intel Group, Rainbow Holdings, Hainan Hai medicine, ST in the source and so on.
From the plate performance, the weaker first half of the pharmaceutical sector, since June before the market bottomed plate, slightly stronger than the performance of the last month, the Shanghai index, the Shanghai index fell in August to 4.99%, the pharmaceutical index fell 3.77 to vote %, stronger than the Shanghai index.
Currently, the overall pharmaceutical sector is still at historically low valuation levels, closing on August 31 pharmaceutical sector price-earnings ratio 27.5 times.